Company Overview Our People Senior Management J. Donald deBethizy, Ph.D. Merouane Bencherif, M.D., Ph.D. Jeffrey P. Brennan William S. Caldwell, Ph.D. Geoffrey C. Dunbar, M.D. Alan A. Musso, C.P.A., C.M.A. Peter A. Zorn, Esq. Mauri K. Hodges, C.P.A., C.C.P. Karen A. Hicks Board of Directors Committee Composition Our History Our Community Winston-Salem Business & Industry Winston-Salem Amenities Targacept in the Community Activities Company Awards Product Pipeline AZD3480 (TC-1734) ADHD AZD 1446 (TC-6683) Alzheimer's Disease TC-5619 - Cognitive Dysfunction in Schizophrenia TC-5214 - Major Depressive Disorder TC-5685 - Depression/Anxiety Disorders Science & Technology Targacept's Solution Neuronal Nicotinic Receptors (NNRs) NNRs: How They Work NNRs: Therapeutic Effects NNR Research Capabilities Patents Scientific Articles Research Grants Drug Discovery Pentad™        Business Development Licensing Opportunities Investor Relations Company Profile Corporate Governance 2009 Annual Meeting Stock Information SEC Filings Analyst Coverage Press Releases Annual Reports Investor Calendar Clinical and Scientific Calendar Board of Directors Senior Management Investor Contact Information Request Form Investor FAQ Email Alerts Policy on Rumors Newsroom Press Releases Online Press Kit Event Calendar Careers Current Opportunities Our People Our Values Our Benefits ©2010 Targacept, Inc. Terms of Use Home Directions Contact Site Map  Go